|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
63,610,000 |
Market
Cap: |
414.74(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$3.88 - $8.25 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile MeiraGTx Holdings is a clinical stage gene therapy company with six programs in clinical development and a pipeline of preclinical and research programs. Co.'s focus is on three areas of unmet medical need: ocular, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases and severe forms of xerostomia. Co.'s product candidates include: AAV-RPE65 for the treatment of retinal dystrophy associated with mutations in the RPE65 gene; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of Leber congenital amaurosis 4; as well as AAV-RDH12 for the treatment of RDH12 Mutation-Associated Retinal Dystrophy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,250,000 |
1,250,000 |
Total Buy Value |
$0 |
$0 |
$5,000,000 |
$5,000,000 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
71,500 |
143,000 |
143,000 |
143,000 |
Total Sell Value |
$397,650 |
$853,952 |
$853,952 |
$853,952 |
Total People Sold |
2 |
2 |
2 |
2 |
Total Sell Transactions |
2 |
5 |
5 |
5 |
End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Harris Keith R. |
|
|
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
75,000 |
125,000 |
|
- |
|
Giroux Richard |
CFO & COO |
|
2025-04-22 |
4 |
AS |
$6.00 |
$144,000 |
D/D |
(24,000) |
882,494 |
|
5% |
|
Forbes Alexandria |
PRESIDENT & CEO |
|
2025-04-08 |
4 |
AS |
$5.34 |
$253,650 |
D/D |
(47,500) |
1,408,983 |
|
26% |
|
Zeldin Robert K |
CHIEF MEDICAL OFFICER |
|
2025-02-21 |
4 |
D |
$7.30 |
$43,092 |
D/D |
(5,903) |
136,520 |
|
- |
|
Zeldin Robert K |
CHIEF MEDICAL OFFICER |
|
2025-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
142,423 |
|
- |
|
Giroux Richard |
CFO & COO |
|
2025-02-21 |
4 |
D |
$7.30 |
$463,200 |
D/D |
(63,452) |
906,495 |
|
- |
|
Giroux Richard |
CFO & COO |
|
2025-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
120,000 |
969,947 |
|
- |
|
Wollin Robert J |
GENERAL COUNSEL AND SECRETARY |
|
2025-02-21 |
4 |
D |
$7.30 |
$88,447 |
D/D |
(12,116) |
31,146 |
|
- |
|
Wollin Robert J |
GENERAL COUNSEL AND SECRETARY |
|
2025-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,500 |
43,262 |
|
- |
|
Forbes Alexandria |
PRESIDENT & CEO |
|
2025-02-21 |
4 |
D |
$7.30 |
$482,494 |
D/D |
(66,095) |
1,456,483 |
|
- |
|
Forbes Alexandria |
PRESIDENT & CEO |
|
2025-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
125,000 |
1,522,578 |
|
- |
|
Naylor Stuart |
CHIEF DEV. OFFICER |
|
2025-02-21 |
4 |
D |
$7.30 |
$171,550 |
D/D |
(23,500) |
623,291 |
|
- |
|
Naylor Stuart |
CHIEF DEV. OFFICER |
|
2025-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
646,791 |
|
- |
|
Giroux Richard |
CFO & COO |
|
2025-01-21 |
4 |
AS |
$6.29 |
$150,960 |
D/D |
(24,000) |
849,947 |
|
-20% |
|
Forbes Alexandria |
PRESIDENT & CEO |
|
2025-01-14 |
4 |
D |
$5.77 |
$91,530 |
D/D |
(15,863) |
1,397,578 |
|
- |
|
Forbes Alexandria |
PRESIDENT & CEO |
|
2025-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
30,000 |
1,413,441 |
|
- |
|
Wollin Robert J |
GENERAL COUNSEL AND SECRETARY |
|
2025-01-14 |
4 |
D |
$5.77 |
$16,785 |
D/D |
(2,909) |
20,762 |
|
- |
|
Wollin Robert J |
GENERAL COUNSEL AND SECRETARY |
|
2025-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
23,671 |
|
- |
|
Giroux Richard |
CFO & COO |
|
2025-01-14 |
4 |
D |
$5.77 |
$76,274 |
D/D |
(13,219) |
873,947 |
|
- |
|
Giroux Richard |
CFO & COO |
|
2025-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
887,166 |
|
- |
|
Zeldin Robert K |
CHIEF MEDICAL OFFICER |
|
2025-01-14 |
4 |
D |
$5.77 |
$87,410 |
D/D |
(15,149) |
127,423 |
|
- |
|
Zeldin Robert K |
CHIEF MEDICAL OFFICER |
|
2025-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
142,572 |
|
- |
|
Naylor Stuart |
CHIEF DEV. OFFICER |
|
2025-01-14 |
4 |
D |
$5.77 |
$64,411 |
D/D |
(11,163) |
596,791 |
|
- |
|
Naylor Stuart |
CHIEF DEV. OFFICER |
|
2025-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,750 |
607,954 |
|
- |
|
Forbes Alexandria |
PRESIDENT & CEO |
|
2025-01-08 |
4 |
AS |
$6.30 |
$73,464 |
D/D |
(11,661) |
1,383,441 |
|
-13% |
|
171 Records found
|
|
Page 1 of 7 |
|
|